

CONTENTS

	Page
Abstract (Thai)	(3)
Abstract (English)	(4)
Acknowledgement	(5)
Contents	(6)
List of Tables	(8)
List of Figures	(10)
Abbreviations	(11)
Chapter	
1 Introduction	1
1.1 Introduction	1
1.2 Objectives	3
2 Review of Literature	4
2.1 <i>Streptococcus pneumoniae</i>	4
2.2 Definition of Drug-Resistant <i>Streptococcus pneumoniae</i>	6
2.3 Mechanisms of Antimicrobial Resistance	7
2.4 History of Drug-Resistant <i>Streptococcus pneumoniae</i>	12
2.5 Prevalence of Drug-Resistant <i>Streptococcus pneumoniae</i>	13
2.6 Risk Factors for Infected Drug-Resistant <i>Streptococcus pneumoniae</i>	16
2.7 Clinical Outcome of Infection Caused by Drug-Resistant <i>Streptococcus pneumoniae</i>	17
2.8 Management of Pneumococcal Infectious Diseases	20
2.9 Susceptibility Testing	27
3 Materials and Methods	29
3.1 Setting	29
3.2 Sample Size Calculation	29
3.3 Ethics	30

	Page
3.4 Inclusion and Exclusion Criteria	30
3.5 Methods of Study	31
4 Results	40
5 Discussion	74
6 Conclusion	84
Bibliography	86
Appendix A McFarland	95
Appendix B <i>Streptococcus pneumoniae</i> Collection Form	96
Appendix C Templates for Application of E test Strips	97
Appendix D E test Reading Guide	98
Appendix E Clinical Data Collection Form	99
Appendix F Simplified Acute Physiology Score (SAPS) II	103
Appendix G Pediatric risk of mortality (PRISM) score	104
Vitae	105

LIST OF TABLES

Table	Page
1 NCCLS breakpoints for interpretation of MICs for <i>Streptococcus pneumoniae</i>	7
2 Mechanisms for pneumococcal resistance to macrolides	11
3 β -lactam antibiotics for treatment of drug-resistant pneumococcal pneumonia for adults	22
4 Non β -lactam antibiotics for treatment of drug-resistant pneumococcal pneumonia for adults	23
5 Doses of intravenous antimicrobials for children with pneumococcal infections	26
6 Pneumococcal vaccination for adults	28
7 Pneumococcal vaccination for children \leq 2 year	28
8 MICs interpretation for <i>Streptococcus pneumoniae</i>	35
9 Quality control ranges of MICs for <i>Streptococcus pneumoniae</i> ATCC 49619	35
10 Susceptibility of <i>Streptococcus pneumoniae</i> to penicillin in Southern Thailand stratified by province	41
11 Prevalence of drug resistant <i>Streptococcus pneumoniae</i> in Southern Thailand stratified by selected antibiotic agents	42
12 Multidrug-resistant pneumococci in Southern Thailand	42
13 Pneumococci with intermediate and high level of resistance stratified by specimen source	44
14 Drug-resistant <i>Streptococcus pneumoniae</i> stratified by site of infection (pneumonia, bacteremia and meningitis)	45
15 The MICs for <i>Streptococcus pneumoniae</i> to selected antibiotic agents	46

Table	Page
16 The MICs for <i>Streptococcus pneumoniae</i> stratified by specimen source	47
17 Susceptibility of penicillin-susceptible and penicillin-nonsusceptible <i>Streptococcus pneumoniae</i> to selected antibiotic agents	53
18 Antimicrobial MIC distributions according to penicillin-susceptibility for <i>S. pneumoniae</i> in Southern Thailand	54
19 Antimicrobial MIC distributions according to erythromycin-susceptibility for <i>S. pneumoniae</i> in Southern Thailand	55
20 General characteristics of patients with pneumococcal infection stratified by penicillin susceptibility	57
21 Results of multiple logistic analysis of the potential variable for penicillin-and erythromycin-nonsusceptible <i>Streptococcus pneumoniae</i> infection in adult	59
22 Susceptibility of <i>Streptococcus pneumoniae</i> to penicillin stratified by co-morbidity	60
23 Comparison of difference between penicillin-susceptible and -nonsusceptible among patient who received β -lactam therapy	62
24 Characteristics and outcomes of patients with pneumococcal pneumonia stratified by penicillin susceptibility	64
25 Antibiotic administered and clinical outcome of patient with pneumococcal bacteremia	69
26 Antibiotic pattern and clinical outcome of patient with pneumococcal meningitis	71
27 Clinical outcome and pattern antibiotic use of patients whose microbiological outcome was eradicated	73

LIST OF FIGURES

Figure	Page
1 <i>Streptococcus pneumoniae</i> replicates in pair and lancet-shaped	4
2 Targets, mode of action and mechanisms of resistance of the major classes of antibacterial drugs	8
3 Schematic representation of mechanism of penicillin-resistance in <i>Streptococcus pneumoniae</i>	9
4 Efflux pump, bacteria manufacture protein pumps that pump the antibiotic out so that it does not accumulate to a high enough internal concentration to block protein synthesis	10
5 The penicillin MIC for <i>Streptococcus pneumoniae</i>	48
6 The cefotaxime MIC for <i>Streptococcus pneumoniae</i>	49
7 The imipenem MIC for <i>Streptococcus pneumoniae</i>	50
8 The levofloxacin MIC for <i>Streptococcus pneumoniae</i>	51
9 The erythromycin MIC for <i>Streptococcus pneumoniae</i>	52

ABBREVIATIONS

AIDS	= acquired immunodeficiency syndrome
BaCl ₂ .2H ₂ O	= barium chloride
BaSO ₄	= barium sulfate
°C	= Celsius
CAD	= coronary artery disease
cfu	= colony-forming unit
CI	= confidence interval
CNS	= central nervous system
CO ₂	= carbon dioxide
COPD	= chronic obstructive pulmonary disease
CSF	= cerebrospinal fluid
DRSP	= drug-resistant <i>Streptococcus pneumoniae</i>
E test	= epsilometric test
ESRD	= end state renal disease
g	= gram
µg	= microgram
h	= hour
H ₂ SO ₄	= sulfuric acid
HIV	= Human immunodeficiency virus
I	= intermediately susceptible
ICU	= intensive care unit
IV	= intravenous
kg	= kilogram
M	= mole
mg/kg/d	= milligram per kilogram per day
ml	= milliliter
mm	= millimeter

mm ³	= cubic millimeter
MIC	= minimum inhibitory concentrations
NCCLS	= the National Committee for Clinical Laboratory Standard
No	= number
OR	= odds ratio
PBP	= penicillin binding protein
PO	= by mouth (<i>per os</i>)
q	= every
R	= resistant
S	= susceptible
SD	= standard deviation
SLE	= systemic lupus erythematosus
% V/V	= % volume by volume
WBC	= white blood cell (count)
wks	= weeks
yrs	= years